Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.
Type:
Application
Filed:
December 10, 2009
Publication date:
February 21, 2013
Applicant:
INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors:
Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
Abstract: The present invention relates to novel coumarin derivatives, their carboxamides, pharmaceutical compositions containing them and their uses as drugs for kidney protection, treating drugs of hypertension, cardio-cerebrovascular diseases, non-insulin dependent diabetes, tumor, pre-cancerous lesion, and edemas.
Type:
Grant
Filed:
December 5, 2003
Date of Patent:
December 25, 2012
Assignee:
Institute of Materia Medica Chinese Academy of Medical Sciences
Inventors:
Shiping Xu, Xiaoguang Chen, Song Xu, Lanmin Li, Longfei Xie, Hongyan Li, Yan Li, Guifang Cheng
Abstract: A submicron emulsion of paclitaxel, the preparation method and the use thereof are disclosed. Said paclitaxel submicron emulsion comprises paclitaxel/steroid complex, oil for injection, water for injection, emulsifier, assistant emulsifier and isotonic agent, wherein the mole ratio of paclitaxel to steroid in the complex is 1:0.2˜4; preferably 1:0.25˜2. Said submicron emulsion is useful for the treatment for malignant tumor. The average particle diameter of the submicron emulsion is less than 400 nm and the pH Value is 3.5-6.
Type:
Application
Filed:
October 28, 2010
Publication date:
December 6, 2012
Applicant:
INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Abstract: The present invention relates to use of two microRNAs in detection of lung cancer prognosis and in medicine preparation. Particularly, the invention relates to a composition comprising two small RNA molecules microRNA-150 and microRNA-886-3p, a device comprising the composition used in detection of lung cancer prognosis and in preparation of medicaments for inhibiting mammal and human lung cancer metastasis. Specifically, the expression levels of microRNA-150 and microRNA-886-3p can be used as the prognostic criteria of lung cancer prognosis, wherein high expression level of the gene combination indicates favorable therapeutic effect. The invention also relates to a device detecting the expression levels of microRNA-150 and microRNA-886-3p in mammalian and human lung cancer and a method for detecting the expression levels of microRNA-150 and microRNA-886-3p in samples.
Type:
Application
Filed:
July 9, 2009
Publication date:
August 30, 2012
Applicant:
CANCER INSTITUTE, CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors:
Qimin Zhan, Lühua Wang, Nan Bi, Yongmei Song, Jianzhong Cao, Wenyang Liu
Abstract: The present invention relates to the salts of (+)-13a-(S)-deoxytylophorinine represented by the general formula (I), the preparation method thereof, the pharmaceutical compositions containing them, and their use as medicaments for prevention and/or treatment of cancer and/or inflammation disease.
Type:
Application
Filed:
July 9, 2010
Publication date:
July 26, 2012
Applicant:
INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors:
Shishan Yu, Xiaoguang Chen, Haining Lv, Yan Li, Song Xu, Shuanggang Ma, Zhenjia Liu, Yi Zhang, Jinping Hu
Abstract: A recombinant gene sequence that comprises human SLC gene, antigen gene, and IgG1-Fc fragment gene, wherein the SLC gene is linked upstream to the antigen gene, and the IgG1-Fc fragment is linked downstream to the antigen gene. This invention also relates to the application of the recombinant gene sequence in the preparation of gene vaccine.
Type:
Grant
Filed:
May 9, 2005
Date of Patent:
March 13, 2012
Assignee:
Cancer Institute, Chinese Academy of Medical Sciences
Abstract: The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2?,3?,5?-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy aniline. The invention also discloses the pharmaceutical composition comprising triacetyl-3-hydroxyphenyladenosine. The dosage forms of the said pharmaceutical composition include tablet, capsule, pill, injection, sustained release preparation, controlled release preparation or particulate delivery system. The medicament for treatment or precaution of hyperlipemia prepared by the compound of the invention has the advantages of significant hypolipidemic activity, less toxicity and adverse effect as well as slow metabolism in vivo.
Type:
Application
Filed:
March 10, 2009
Publication date:
March 1, 2012
Applicant:
INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors:
Haibo Zhu, Song Wu, Linghua Hao, Kai Qu, Ping Zhu, Xing Wang, Wei Li
Abstract: This invention discloses that the five crystal forms of XLF-III-43 can be used as crude drugs. The invention also relates to the preparation methods of the five crystal forms of XLF-III-43 as crude drugs, to the applications of the sterling of the five crystal forms of XLF-III-43 and mixed crystals in different proportions as medicinally active components to develop various kinds of medicines and compound medicines. In addition, this invention also relates to applying the crystal samples of XLF-III-43 as crude drugs to treat kidney dysfunction, cardiocerebral vessel diseases, hypertension, type II diabetic mellitus, complications of hypertension and diabetic mellitus, tumor, precancerosis, edema, and achieves therapeutic effects by enhancing blood drug levels resulted from effects of crystal forms in the processes of treating all kinds of diseases.
Type:
Application
Filed:
November 28, 2009
Publication date:
December 29, 2011
Applicant:
INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors:
Yang Lv, Xiaoguang Chen, Ping Xie, Li Zhang, Cheng Wang
Abstract: The invention relates to a method for preparing polyepitope chimeric gene vaccines, designated as Epitopes Assemble Library Immunization (EALI). It involves the construction of expression libraries of polyepitope chimeric genes with different sizes and lengths using gene shuffling and random assembly so as to screen polyepitope chimeric gene vaccines. Immunization of the body with the gene libraries of the invention results in the induction of high level of specific antibodies and specific types of cytokines, and protection on the body.
Type:
Grant
Filed:
August 1, 2003
Date of Patent:
July 19, 2011
Assignees:
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
Abstract: The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage of the compound 1-deoxynojirimycin is 30% or more by weight in the total alkaloids. The effective fraction of the invention is prepared as the following steps: the mulberry twig is extracted by solvents, and the extract is precipitated by alcohol precipitation or flocculation to remove the impurities, and then concentrated, purified by resin chromatography. The present invention also relates to a pharmaceutical composition containing the said effective fraction of alkaloids and to the use of the effective fraction of alkaloids according to claim 1-4 in preparing hypoglycemic agents.
Type:
Application
Filed:
August 22, 2007
Publication date:
June 2, 2011
Applicant:
Institute of Materia Medica Chinese Academy of Medical Sciences
Abstract: The characterization of a new strain of human rhinovirus of genetic group C(HRV-C) as well as methods and kits for detecting the presence of HRV-C by PCR amplification are provided.
Type:
Application
Filed:
April 16, 2009
Publication date:
May 12, 2011
Applicants:
BIOMERIEUX, INSTITUTE OF PATHOGEN BIOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES, BEIJING CHILDREN'S HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIVERSITY
Inventors:
Richard Gonzalez, Jianwei Wang, Zichun Xiang, Kunling Shen
Abstract: The present invention discloses a monoclonal antibody against the extracellular domain of human tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 (death receptor 5). The present invention also provides a method of producing the monoclonal antibody, amino acid sequences of the variable regions of the monoclonal antibody's heavy chain and light chain, as well as use of the monoclonal antibody for preparation of a medicament in the treatment of various cancers and/or AIDS.
Type:
Grant
Filed:
March 7, 2005
Date of Patent:
February 22, 2011
Assignee:
The Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences
Abstract: The present invention discloses cephalomannine derivatives of general formula (I), a process for preparation of such cephalomannine derivatives, a composition containing such compounds, and use of said compounds in the manufacture of a medicament for the treatment of tumors, especially multidrug resistant tumors.
Type:
Application
Filed:
November 15, 2007
Publication date:
February 17, 2011
Applicant:
INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.
Type:
Application
Filed:
December 25, 2007
Publication date:
February 10, 2011
Applicant:
INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES
Abstract: A set of geldanamycin derivatives and their preparation methods. Pharmaceutical compositions comprising the said compounds as an active ingredient which are used as antivirus and antitumor agents. The said derivatives are used in the manufacture of heat shock protein 90 (Hsp 90) inhibiting agents which have the utility as antivirus and antitumor agents.
Type:
Application
Filed:
January 19, 2009
Publication date:
December 9, 2010
Applicant:
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Abstract: This invention discloses novel quinolonecarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof, and their preparation methods and medical uses. The compounds in this invention show potent antibacterial activity against broad-spectrum pathogenic bacteria, with favorable pharmacokinetics and very low toxicity. The quinolinecarboxylic acid derivatives, which possess a hydrogen atom or an amino group at C-5 position, cis-substituted optical or racemic 2,8-diazo-dicyclo[4,3,0]nonanyl at C-7 position, and difluoromethoxyl at C-8 position of quinolone core, have superior activity against gram-positive bacteria and broad spectrum antibacterial activity compared with the known quinolones.
Type:
Grant
Filed:
April 13, 2005
Date of Patent:
July 20, 2010
Assignees:
Institut of Medicinal Biotechnology Chinese Academy of Medical Sciences, Xinchang Pharmaceutical Factory, Zhejiang Medicine Co. Ltd.
Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.
Type:
Application
Filed:
June 13, 2006
Publication date:
June 17, 2010
Applicant:
Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences
Inventors:
Chengyu Jiang, Feng Guo, Shuan Rao, Bing Guan, Yi Huan, Peng Yang
Abstract: The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by ?-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.
Type:
Grant
Filed:
December 31, 2003
Date of Patent:
July 7, 2009
Assignee:
Institute of Materia Medica, Chinese Academy of Medical Science
Inventors:
Jianjun Zhang, Jiangong Shi, Yafang Wang, Dan Zhang, Mei Gao, Yongchun Yang, Shengyang Huang
Abstract: The invention relates to new synthetic 2-(?-hydroxypentyl) benzoates, their preparation and pharmaceutical compositions containing such salts as active ingredients. The invention also relates to the use of the compounds for preventing and treating cardioischemia, cerebroischemia and cardiac or cerebral arterial occlusion (obstruction), etc.
Type:
Grant
Filed:
May 9, 2002
Date of Patent:
June 23, 2009
Assignee:
Institute of Materia Medica, Chinese Academy of Medical Sciences